WO2010065799A3 - Amine substituted piperidine melanocortin receptor-specific compounds - Google Patents

Amine substituted piperidine melanocortin receptor-specific compounds Download PDF

Info

Publication number
WO2010065799A3
WO2010065799A3 PCT/US2009/066668 US2009066668W WO2010065799A3 WO 2010065799 A3 WO2010065799 A3 WO 2010065799A3 US 2009066668 W US2009066668 W US 2009066668W WO 2010065799 A3 WO2010065799 A3 WO 2010065799A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific compounds
melanocortin receptor
substituted piperidine
amine substituted
melanocortin
Prior art date
Application number
PCT/US2009/066668
Other languages
French (fr)
Other versions
WO2010065799A2 (en
Inventor
James Bullington
Axel Metzger
Original Assignee
Palatin Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies, Inc. filed Critical Palatin Technologies, Inc.
Publication of WO2010065799A2 publication Critical patent/WO2010065799A2/en
Publication of WO2010065799A3 publication Critical patent/WO2010065799A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of the formula I, where R1, R2a, R2b, R3, L1, L2, Q, J, X, m and n are as defined, or an enantiomer. stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, syndromes and conditions/ modulated by melanocortin-receptors.
PCT/US2009/066668 2008-12-04 2009-12-04 Amine substituted piperidine melanocortin receptor-specific compounds WO2010065799A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11989308P 2008-12-04 2008-12-04
US61/119,893 2008-12-04

Publications (2)

Publication Number Publication Date
WO2010065799A2 WO2010065799A2 (en) 2010-06-10
WO2010065799A3 true WO2010065799A3 (en) 2010-07-29

Family

ID=41724750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/066668 WO2010065799A2 (en) 2008-12-04 2009-12-04 Amine substituted piperidine melanocortin receptor-specific compounds

Country Status (1)

Country Link
WO (1) WO2010065799A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
CN102464654B (en) * 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 Antiviral compound
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
DK3539551T3 (en) 2011-12-29 2021-11-01 Rhythm Pharmaceuticals Inc Method for the treatment of melanocortin-4 receptor-associated disorders in heterozygous carriers
WO2015175171A1 (en) * 2014-04-23 2015-11-19 X-Rx Discovery, Inc. Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases
MA43040A (en) 2015-09-30 2018-08-08 Univ Berlin Charite METHOD OF TREATMENT OF DISORDERS ASSOCIATED WITH THE MELANOCORTIN 4 RECEPTOR PATH
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020060983A2 (en) * 2018-09-18 2020-03-26 Palatin Technologies, Inc. Orally active melanocortin receptor-4 compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096296A1 (en) * 2000-06-13 2001-12-20 Eli Lilly And Company Serine protease inhibitors
WO2002070511A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
WO2005047251A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ES2117642T3 (en) 1990-05-10 1998-08-16 Bechgaard Int Res PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETILEN GLYCOLS.
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
DE69705746T2 (en) 1996-12-20 2001-10-31 Alza Corp INJECTABLE DEPOT GEL PREPARATION AND PRODUCTION METHOD
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
JP2002531549A (en) 1998-12-04 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー 3-Substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096296A1 (en) * 2000-06-13 2001-12-20 Eli Lilly And Company Serine protease inhibitors
WO2002070511A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
WO2005047251A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESSAWI M Y H ET AL: "Synthesis and evaluation of 1- and 2-substituted fentanyl analogues for opioid activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 26, 1 January 1983 (1983-01-01), pages 348 - 352, XP002244810, ISSN: 0022-2623 *
YEON SUN LEE ET AL.: "Opioid and Melanocortin Receptors: Do they have Overlapping Pharmacophores?", BIOPOLYMERS , 90(3), 433-438 CODEN: BIPMAA; ISSN: 0006-3525, 26 July 2007 (2007-07-26), XP002572314 *

Also Published As

Publication number Publication date
WO2010065799A2 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
WO2010065799A3 (en) Amine substituted piperidine melanocortin receptor-specific compounds
IL200720A0 (en) Metabolically engineered microorganism useful for the production of 1,2-propanediol
HUS1900034I1 (en) 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
EP1911743B8 (en) Cyclic amine compound
PL1993985T3 (en) Process for the preparation of 1,2-propanediol
EP1947076A4 (en) Process for producing aromatic compound and aromatic compound obtained by the process
WO2009048101A1 (en) Amide compound
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
EP1746085A4 (en) Aromatic amine derivative, organic electroluminescent element employing the same, and process for producing aromatic amine derivative
EA201100919A1 (en) SPIROHETEROCYCLIC N-OXYPIPERIDINES AS PESTICIDES
IL188606A0 (en) Novel 1,4-benzothiazepine-1,1-dioxide, derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
EP2216312A4 (en) Process for producing organic compound and organic compound obtained by the same
MX280092B (en) Process for producing 5-hydroxy-4-thiomethylpyrazole compound.
WO2008019395A3 (en) Compounds for improving learning and memory
PL2420491T3 (en) 3 , 5-substitued piperidine compounds as renin inhibitors
IL192227A0 (en) Amorphous form of 1,2-dihydropyridine compound
ATE531717T1 (en) NEW CRYSTALLINE FORM OF A PYRIDAZINOÄ4.5 BÜINDOL DERIVATIVE
WO2008110281A3 (en) 3,4-disubstituted phenoxyphenylamidines and use thereof as fungicides
WO2005121078A3 (en) Substituted cyclopentene compounds
WO2010066629A3 (en) Novel azaindoles
WO2008153154A1 (en) Cyclic compound, photoresist base material and photoresist composition
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009068463A9 (en) Process for the preparation of isoindole derivatives as well as a process for the preparation of their intermediates
WO2009055289A3 (en) Therapeutic substituted lactams

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09795598

Country of ref document: EP

Kind code of ref document: A2